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Abstract
Background: Glucose homeostasis improves within days following Roux-en-Y gastric bypass (RYGB) surgery. The
dynamic metabolic response to caloric intake following RYGB has been assessed using liquid mixed meal tolerance
tests (MMTT). Few studies have evaluated the glycemic and hormonal response to a solid mixed meal in subjects
with diabetes prior to, and within the first month following RYGB.
Methods: Seventeen women with type 2 diabetes of less than 5 years duration participated. Fasting measures of
glucose homeostasis, lipids and gut hormones were obtained pre- and post-surgery. MMTT utilizing a solid 4 oz
chocolate pudding performed pre-, 2 and 4 weeks post-surgery. Metabolic response to 4 and 2 oz MMTT assessed
in five diabetic subjects not undergoing surgery.
Results: Significant reductions in fasting glucose and insulin at 3 days, and in fasting betatrophin, triglycerides and
total cholesterol at 2 weeks post-surgery. Hepatic insulin clearance was greater at 3 days post-surgery. Subjects
exhibited less hunger and greater feelings of fullness and satisfaction during the MMTT while consuming 52.9 ± 6.
5% and 51.0 ± 6.5% of the meal at 2 and 4 weeks post-surgery respectively. At 2 weeks post-surgery, glucose and
insulin response to MMTT were improved, with greater GLP-1 and PYY secretion. Improved response to solid MMTT
not replicated by consumption of smaller pudding volume in diabetic non-surgical subjects.
Conclusions: With a test meal of size and composition representative of the routine diet of post-RYGB subjects,
improved glycemic and gut hormone responses occur which cannot be replicated by reducing the size of the
MMTT in diabetic subjects not undergoing surgery.
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Background
Bariatric surgery is an effective means of promoting sig-
nificant long-lasting weight loss with concomitant im-
provement and/or resolution of diabetes and other
associated co-morbidities. Of great interest is the obser-
vation that the Roux-en-Y gastric bypass (RYGB) proced-
ure improves both fasting and dynamic measures of
glucose homeostasis well before significant weight loss,
resulting in the concept that RYGB surgery “cures dia-
betes” through mechanism(s) that are separable from
weight loss itself [1–4]. As recently reviewed [5] possible
weight lost independent mechanisms include the signifi-
cant caloric restriction that reduces hepatic and pancre-
atic fat, the exclusion of nutrients from the duodenum,
and the more rapid entry of nutrients into the distal
small intestine with concomitant increased release of
bile acids and gut hormones such as glucagon-like pep-
tide 1 (GLP-1). While it is likely that no one mechanism
is solely responsible for the acute improvements in
glucose homeostasis, studies designed to test each mech-
anism independently often require post-surgery patients
to engage in ingestive behavior that is not congruent
with the intent of the surgery, such as consuming large
caloric loads that match pre-surgery intake and which
do not reflect the behavioral responses that occur post-
surgery.
Mixed meal tolerance tests are often used to assess dy-
namic measures of glucose homeostasis because they are
a physiologically relevant challenge that mimics the free
living condition. In the bariatric literature many studies
use commercially available liquid mixed meals with var-
ied macronutrient content [6–10]. However, a liquid
meal may not induce all the postprandial effects of solid
meal consumption. For example, it has been argued that
liquids are not as effective as solids in inducing cephalic
phase responses in insulin or pancreatic polypeptide re-
lease [11, 12]. Liquids require less oral processing, have
more rapid gastric-emptying and orocecal transit times
[13, 14], and evoke lower expected satiation in non-
bariatric subjects [15, 16]. Cognitive manipulations of
energy content and portion size can also significantly
influence appetitive ratings and subsequent energy in-
take [17–19], with the perceived energy content of a
food better predicting self-reported appetitive sensa-
tions than the true energy content [20, 21]. Finally, it
has been shown that the cognitive and sensory effects
of food form alter ingestive behavior with oral-liquid
and perceived gastric-liquid preloads eliciting greater
postprandial hunger and lower fullness sensations,
more rapid gastric-emptying and orocecal transit
times, attenuated insulin and glucagon-like peptide 1
release, and lower ghrelin suppression than did re-
sponses after oral-solid and perceived gastric-solid
treatments [22].
In the present study we utilized a solid mixed meal to
examine the effect of RYGB surgery to alter the behav-
ioral and metabolic response to caloric challenge at 2
and 4 weeks post-surgery in subjects with short duration
type 2 diabetes. We also assessed acute changes in fast-
ing glucose, lipids, betatrophin (as a marker of insulin
resistance [23]) and gut hormones over the same time
period. Our goal was to examine metabolic responses to
caloric intake that mimicked real life conditions follow-
ing RYGB surgery.
Methods
Subjects
Eighteen women scheduled for RYGB surgery were
recruited, with 17 completing the full study. One
subject was unable to complete all the required
procedures due to post-operative complications im-
mediately following surgery. Inclusion criteria were
morbidly obese (BMI > 35 kg/m2), 20–60 years old,
with documented type 2 diabetes (fasting plasma
glucose > 126 mg/dl or >200 mg/dl 2 h after 75 g
OGTT), with total disease duration of 5 years or less
at screening visit, and HbA1c ≤ 8.5%. Diabetes was
managed either by lifestyle modification (drug naïve),
oral medications, or with insulin (maximum daily
total dose ≤ 50 units). Injectable GLP-1 analogs or
oral DPP-4 inhibitors were discontinued at least
1 week prior to pre-surgery visit. At initial contact
with the surgeons’ office subjects were prescribed a
low carbohydrate, whole food liver reduction diet to
teach the better food choices that would be required
following surgery.
Five subjects not scheduled for bariatric surgery (1
women and 4 men; BMI 39.4 ± 2.7 kg/m2; age 47 ± 4 y)
and meeting the inclusion criteria detailed above were
recruited from the general population to assess the hor-
monal response to two different solid test meal (pud-
ding) volumes. Three subjects were on metformin and
two subjects were drug naïve at the time of testing.
All subjects gave informed consent and the protocol
was approved by the Institutional Review Boards at Indi-
ana University-Purdue University and Community Hos-
pitals, Indianapolis, Indiana.
Procedures
Subjects participated in a baseline visit that occurred
within the 2 weeks prior to their RYGB surgery, and
visits at 3 days, 1, 2 and 4 weeks post-surgery. An-
thropometrics and fasting blood samples were obtained
at all visits. Meal tolerance tests were performed pre-
surgery and at 2 and 4 weeks post-surgery. The identical
surgical procedure was performed by two surgeons and
included a 1 oz gastric pouch, 100 cm Roux and 50 cm
biliopancreatic limb.
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Mixed meal tolerance test (MMTT)
A temporary indwelling catheter for venous access and
sampling was placed and kept patent with saline.
Bariatric subjects were provided a 4 oz pudding
(~140 ml) consisting of 52.5 g whey protein, 25.0 g
carbohydrate (11.1 g sugar) and 8.8 g fat. Subjects were
instructed to consume the pudding within 15 min, and
to eat until they were full (subjects did not have to finish
the pudding). Pudding consumed was determined by
weigh back. The time zero blood sample was drawn and
then the subjects began to eat. Subjects interrupted eat-
ing for ~ 30–60 s for the blood draw at 10 min. All sam-
ples were drawn by syringe and immediately placed into
BD P700 inhibitor tubes kept on ice. Samples were spun
at 4 °C, aliquoted and frozen on dry ice within 10 min of
the draw.
In the pilot effort to examine the metabolic effect of 4
versus 2 oz of pudding, subjects not scheduled for bar-
iatric surgery were randomly assigned in a crossover de-
sign to consume one volume of pudding at the first visit,
and to consume the other volume at a second visit at
least 1 week later. Blood samples were drawn and proc-
essed as above.
Behavioral assessments
Subjects rated their hunger, fullness, how much they
could eat, satisfaction, nausea and energy level on
horizontally oriented 100 mm Visual Analog Scales.
Ratings were completed at baseline, 30 and 120 min dur-
ing the meal test.
Assays
Glucose, triglycerides, cholesterol, apolipoproteins, insu-
lin and C-peptide were measured using standard clinical
analyzer methods on an ADVIA Centaur and Roche
Modular system. Total GLP-1 was measured by radio-
immunoassay (Millipore [Billerica, MA]; within CV =
22%, between CV = 23% at 20pM), active GLP-1 by
Meso Scale Electrochemiluminescence ([Rockville, MD];
within CV = 9.3%, between CV = 3.6% at 0.7 and 1.3 pM
respectively), and pancreatic peptide YY (PYY) by ELISA
(Millipore [Billerica, MA]; within CV = 2.66%, between
CV =6.93% at 9.7 pM). For active GLP-1, values at the
limit of detection were assigned a value of 0.65, the low-
est standard in the assay. Measures made on samples
from the 5 subjects in the pilot effort on pudding
volume were done in the Considine lab at Indiana
University. Glucose was measured using a Randox
Daytona Clinical Analyzer, with insulin (within CV =
3.1%, between CV = 6.0% at 8.0 μU/ml) and c-peptide
(within CV = 3.4%, between CV = 9.3% at 0.4 ng/ml)
measured by radioimmunoassay (Millipore; Billerica,
MA). Betatrophin was measured by ELISA (Phoenix
Pharmaceuticals Inc [Burlingame, CA]; within CV = 8.9%
at 1 ng/ml). HbA1c was measured by HPLC in the hos-
pital lab as part of the subject’s pre-surgery blood work.
Statistical analysis
Values are reported as mean ± SEM. Insulinogenic
index was calculated by dividing the increment in in-
sulin or c-peptide during the first 30 postprandial
minutes by the increment in glucose over the same
period. Hepatic insulin clearance was estimated by
the molar ratio of fasting C-peptide to insulin [24].
Total area under the curve (AUC) was calculated for
all measures except gut peptides, for which incre-
mental AUC was used. To assess the significance of
changes over time, data were analyzed by repeated
measures ANOVA followed by Tukey’s multiple
comparison test. Friedman test followed by Dunn’s
Multiple Comparison Test was used for groups with
unequal variance. Analyses were conducted with
GraphPad Prism 5. Statistical significance was set at
P < 0.05.
Results
Seventeen women (BMI 53.3 ± 3.5 kg/m2; age 45 ± 10 y)
with well-controlled type 2 diabetes (HbA1c 6.5 ± 0.7%)
completed the study. The average duration of diabetes
was 3.1 ± 1.7 years. Prior to surgery 14 subjects were
taking antihyperglycemic therapy (7 on metformin, 1 on
sulfonylurea, 3 on pioglitazone, 1 on GLP-1 analog, 1 on
DPPIV inhibitor, and 1 on insulin), with 3 subjects not
on any antihyperglycemic drugs. All subjects stopped
their antihyperglycemic medications prior to surgery,
and none required antihyperglycemic treatment follow-
ing surgery.
Subjects lost weight over the course of the study, achiev-
ing a significant reduction beginning at 1 week post-
surgery (143.8 ± 9.2, 140.6 ± 9.2, 135.8 ± 9.2, 131.0 ± 8.7 kg,
for pre-surgery, 1, 2, and 4 weeks respectively; P < 0.05).
As illustrated in Table 1, there were significant reductions
in fasting glucose and insulin at 3 days post-surgery that
were maintained over the course of the study. Fasting C-
peptide was significantly lower only at 3 days and 1 week
post-surgery. Hepatic insulin clearance significantly in-
creased beginning at day 3. Triglycerides and total choles-
terol were significantly lower at 2 weeks post-surgery.
HDL cholesterol was significantly reduced beginning at
1 week post-surgery but there was no significant change
in LDL cholesterol.
Fasting betatrophin was significantly reduced at
2 weeks post-surgery. There was no correlation between
fasting betatrophin and fasting glucose, insulin or tri-
glycerides at the pre- or post-surgery time points. There
was also no relationship between the reduction in beta-
trophin at 2 weeks post-surgery and the reductions in
glucose, insulin or triglycerides.
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Subjective responses to meal challenge
Subjects consumed 100% of the pudding provided prior
to surgery, but only 52.9 ± 6.5% and 51.0 ± 6.5% of the
pudding at 2 and 4 weeks post-surgery (P < 0.0001). As
illustrated in Fig. 1, subjects began the meal test at 2 and
4 weeks post-surgery with significantly less hunger (P =
0.014) and lower expectation of amount they could eat
(P = 0.012), with greater feelings of fullness (P = 0.001)
and satisfaction (P = 0.001), compared to pre-surgery.
AUCtotal for hunger and how much subjects could eat
was significantly less, with that for fullness and satisfac-
tion significantly greater at 2 and 4 weeks post-surgery
(Table 2). Nausea was low with energy level moderate
and not different during the three meal tests.
Hormonal responses to meal challenge
Fasting glucose and insulin were significantly lower at
the start of the 2 and 4 week post-surgery meal test
(Table 1, Fig. 2). In contrast to pre-surgery, glucose and
insulin exhibited a rapid rise that peaked at 30 min, and
returned to baseline by the end of the MMTT (Fig. 2).
Fasting C-peptide did not differ across the three MMTT.
However, during the two post-surgery MMTT, C-
peptide exhibited a more parabolic response with peak
Table 1 Fasting measures of glucose homeostasis and lipids
Pre-Surgery Post-Surgery
3 days 1 week 2 week 4 week
Glucose [mg/dl] 131.6 ± 9.3 102.6.6 ± 6.0* 103.1 ± 5.0* 106.9 ± 4.8* 105.5 ± 3.7*
Insulin [uU/ml] 21.2 ± 3.1 9.8 ± 1.5* 10.9 ± 1.3* 14.0 ± 1.8* 12.7 ± 1.4*
C-peptide [ng/ml] 4.2 ± 0.3 2.7 ± 0.3* 2.9 ± 0.3* 3.5 ± 0.3 3.5 ± 0.3
Hepatic Insulin Clearance 10.7 ± 0.7 14.2 ± 0.9* 13.4 ± 0.6* 13.7 ± 1.2* 14.0 ± 0.8*
Triglycerides [mg/dl] 169.5 ± 16.3 146.8 ± 8.2 127.5 ± 7.4* 129.1 ± 8.4*
Total Cholesterol [mg/dl] 178.4 ± 9.6 164.2 ± 7.0 151.5 ± 7.4* 148.6 ± 7.4*
LDL Cholesterol [mg/dl] 105.0 ± 8.6 103.9 ± 7.0 100.9 ± 8.5 88.9 ± 6.9
HDL Cholesterol [mg/dl] 39.6 ± 2.2 30.9 ± 1.5* 32.1 ± 1.1* 33.8 ± 2.2*
Apo A1 [mg/dl] 131.6 ± 5.0 106.1 ± 3.5 103.8 ± 4.9
Apo B [mg/dl] 96.4 ± 7.1 104.0 ± 5.9 85.5 ± 5.7
Betatrophin [ng/ml] 2.6 ± 0.4 1.6 ± 0.1*
*P < 0.05 compared to Pre-Surgery
Fig. 1 Hunger and satiety ratings during the pre- and post-surgery solid meal test. Pre-surgery AUCtotal for each measure significantly different
(P < 0.05) from that at 2 and 4 weeks post-surgery. See Table 2
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at 30–60 min, and values approaching baseline by
120 min.
Insulinogenic index calculated using the change in in-
sulin over the first 30 min was significantly lower at
2 weeks post-surgery (0.65 ± 0.22 vs 0.22 ± 0.03 nmol/
mmol; P = 0.0095) but not at 4 weeks (0.27 ± 0.04 nmol/
mmol). Insulinogenic index calculated using C-peptide
was also significantly lower at 2 weeks post-surgery
(1.94 ± 0.68 vs 0.73 ± 0.09 nmol/mmol; P = 0.0209) but
not at 4 weeks (0.92 ± 0.13 nmol/mmol). AUCtotal for
glucose and insulin were significantly reduced at both 2
and 4 weeks post-surgery but C-peptide AUCtotal was
not significantly different across the study (Table 3). The
ratio of AUC C-peptide/AUC glucose was not differ-
ent across the study (0.32 ± 0.03, 0.32 ± 0.03, 0.30 ±
0.02 nmol/mmol). The ratio of AUC insulin/AUC c-
peptide was significantly reduced at 2 and 4 weeks
post-surgery compared to the pre-surgery value (8.9 ±
0.5, 6.3 ± 0.4, 5.80.4, respectively; P < 0.05).
There was little release of active GLP-1 during the
pre-surgery MMTT (Fig. 2). In contrast active GLP-1
increased significantly during the two post-surgery chal-
lenges, peaking at 30 min and returning to baseline by
120 min. The incremental AUC for active GLP-1 was
significantly greater at 2 and 4 weeks post-surgery as
was AUCI for total GLP-1. Fasting PYY was significantly
reduced at 1 week post-surgery (35.3 ± 3.2 vs 23.9 ± 2.0
pmol/L; P = 0.001). PYY exhibited a greater AUC during
the MMTT only at 2 weeks post-surgery (Table 3).
Effect of pudding volume on metabolic response to
meal test
To evaluate the effect of ingesting different pudding vol-
umes on metabolic responses, five subjects with diabetes
consumed 2 or 4 oz of pudding on separate days. As
shown in Fig. 3, glucose was elevated at the start of both
meal tests, and exhibited a flat response curve similar to
that of the bariatric subjects pre-surgery (Fig. 2). Also as
observed for the pre-surgery subjects, insulin levels
peaked at 60 min and did not return to baseline at
120 min with either pudding volume. C-peptide re-
sponse was the same with both pudding volumes and
did not exhibit a trend for return to baseline at 120 min.
Insulinogenic index calculated using the change in insu-
lin (0.50 ± 0.26 vs 0.48 ± 0.14 nmol/mmol) or C-peptide
(0.82 ± 0.4 vs 2.3 ± 1.2 nmol/mmol) was not significantly
different by pudding volume. Glucose AUCtotal was
Fig. 2 Glycemic and hormonal response to solid meal test is improved following RYGB surgery. Pre-surgery AUCtotal for glucose, insulin and active
GLP-1 significantly different (P < 0.05) from that at 2 and 4 weeks post-surgery. See Table 3
Table 2 AUCtotal for subjective responses during meal test at 2
and 4 weeks post-surgery
Pre-
Surgery
Post-Surgery
2 week 4 week
Hunger 3231 ± 596 1474 ± 469* 1293 ± 283*
How Much Can You Eat 4812 ± 524 1411 ± 273* 2104 ± 1669*
Feeling of Fullness 4435 ± 706 8073 ± 658* 9002 ± 431*
Feeling of Satisfaction 6105 ± 609 8481 ± 767* 8538 ± 771*
Nausea 1218 ± 511 1771 ± 613 2078 ± 649
Energy Level 6324 ± 716 7313 ± 515 7142 ± 505
*P < 0.05 compared to Pre-Surgery
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slightly less with consumption of 2 oz of pudding com-
pared to that following 4 oz (19890 ± 3918 vs 20971 ±
4144 mg/dl x min respectively; P = 0.016), but remained
comparable to that observed for the pre-surgery meal
test. C-peptide AUCtotal (415 ± 36 vs 443 ± 71 ng/ml x
min) and insulin AUCtotal (4153 ± 515 vs 7046 ± 154 uU/
ml x min) were not statistically different by pudding vol-
ume, although the lower insulin excursion with the 2 oz
meal suggests greater insulin clearance. There was no
difference in AUCtotal for hunger (5313 ± 985 vs 3981 ±
1349), how much subjects could eat (7029 ± 1639 vs
6336 ± 1680), fullness (5754 ± 1553 vs 6717 ± 1149) or
satisfaction (6972 ± 1709 vs 9021 ± 739) with consump-
tion of 2 or 4 oz of pudding. These data indicate that in
the absence of surgery, consuming a meal of smaller vol-
ume does not improve the glycemic, insulin secretory or
behavioral response to a test meal in obese subjects with
diabetes.
Discussion
Subjects undergoing RYGB lost a modest amount of
weight over the four weeks following surgery, and none
needed to resume antihyperglycemic therapy following
surgery. There were significant reductions in fasting glu-
cose and insulin, with a significant increase in hepatic
insulin clearance, as early as 3 days after surgery. Fasting
betatrophin, triglycerides, total cholesterol, and HDL
were significantly decreased post-surgery. Subjects ex-
hibited less hunger, lower expectation of the amount of
food they could eat, and greater feelings of fullness and
satisfaction during the meal test following surgery, at
which they consumed ~50% less calories. Insulinogenic
index and AUC for glucose and insulin were significantly
lower at 2 weeks post-surgery. GLP-1 and PYY response
to the meal was significantly increased post-surgery. The
improvement in metabolic responses to the meal chal-
lenge following surgery could not be replicated by simply
reducing meal volume in similar subjects who did not
undergo surgery.
Acute reductions within the first post-operative week
in fasting measures of glucose homeostasis support the
suggestion that bariatric surgery ameliorates diabetes
[1–4] and this effect appears to be primarily driven by
changes in hepatic metabolism. Increased hepatic insulin
sensitivity, decreased hepatic glucose production and in-
creased hepatic insulin clearance have all been observed
within the first post-operative month [25–28], beginning
as early as 1 week following surgery [9, 29]. Several stud-
ies suggest that the improvement in hepatic metabolism
is primarily due to the caloric restriction rather than the
surgery per se [27, 30, 31]. However it is important to
Table 3 AUC for glucose and hormone excursions during meal
test at 2 and 4 weeks post-surgery
Pre-Surgery Post-Surgery
2 weeks 4 weeks
Glucose [mg/dl x min] 17,229 ± 1199 14,158 ± 666* 13,776 ± 509*
Insulin [uU/ml x min] 8027 ± 943 5142 ± 914* 4354 ± 701*
C-peptide [ng/ml x min] 857 ± 60 748 ± 81 688 ± 60
Active GLP-1 [pmol/L x min] 137 ± 29 943 ± 221* 778 ± 196*
Total GLP-1 [pmol/L x min] 1034 ± 317 3717 ± 668* 3428 ± 668*
PYY [pmol/L x min] 196 ± 160 2874 ± 643* 2058 ± 544*
*P < 0.05 compared to Pre-Surgery
Fig. 3 Reductions in meal size do not normalize the glycemic and
hormonal response to caloric challenge in subjects with type 2
diabetes. Glucose AUCtotal following consumption of 2 oz of
pudding lower than after 4 oz (P = 0.016). Insulin and C-peptide
AUCtotal not significantly different by pudding size
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note that the degree of caloric restriction following
RYGB surgery is difficult to achieve and maintain in the
non-surgical population. Our data showing that subjects
exhibited less hunger, lower expectation of the amount
of food they could eat, and greater feelings of fullness
and satisfaction in the fasting state support the efficacy
of RYGB surgery to reduce caloric intake. It should be
noted that the consumption of a low glycemic liver re-
duction diet prior to surgery was not sufficient to
normalize hepatic metabolism to that attained following
RYGB surgery.
Fasting triglycerides and total cholesterol significantly
improved beginning at 2 weeks post-surgery, with a sig-
nificant reduction in HDL at 1 week following surgery.
A recent meta-analysis of data from 7815 subjects that
underwent RYGB surgery found that, although hetero-
geneity among the studies included was high, triglycer-
ides were significantly reduced by 3 months, total
cholesterol and LDL by 1 month, and that HDL was un-
changed until an increase at 1 year post-surgery [32].
The acute improvement in lipids observed here can
likely be attributed to both reduced food intake, and re-
duced lipid absorption [33–35].
Betatrophin, or angiopoietin-like protein 8, is expressed
in human liver and adipose tissue, is present in the
circulation, and is involved in triglyceride metabolism
[36]. Preclinical studies had suggested that betatrophin
promoted β-cell proliferation [37] but this work has
recently been retracted [38]. Betatrophin has also been
suggested to be a marker of insulin resistance, although
the nature of the relationship (positive or negative) is
controversial, likely due to small differences in circulating
protein across populations of different adiposity or dia-
betic status, and to differences in the commercially avail-
able human betatrophin assays [23]. In the current study
we observed a small but significant reduction in fasting
betatrophin at 2 weeks post-surgery, suggesting that beta-
trophin is increased in the diabetic state and reduced with
normalization of insulin levels, although there was no cor-
relation between betatrophin and fasting glucose, insulin
or triglycerides. It is important to note that the assay used
here employs an antibody targeted to the carboxy
terminus of betatrophin, which has been shown to detect
both full length and carboxy-terminal cleavage fragments
of the protein [23]. Thus the reduction in betatrophin ob-
served here is unlikely to be due to increased degradation
of protein. A recent study has shown that insulin infusion
increases adipocyte betatrophin expression in humans
[39]. Thus it is possible that the reduction in circulating
insulin following bariatric surgery decreases the signal for
betatrophin production in adipose tissue.
In response to solid meal test following surgery, sub-
jects experienced less hunger, lower expectation of the
amount of food they could eat, and greater feelings of
fullness and satisfaction, coincident with consumption of
only 50% of the meal provided. Given that the volumes
of liquid meal tests used in the bariatric literature range
from 100 to more than 400 mls [5–9 and others] it is
note-worthy that subjects in the current study only com-
fortably consumed about 70 mls following surgery. Fac-
tors that likely contributed to this outcome include the
high protein content of the pudding, the slower more
deliberate act of eating the pudding with a spoon, and
individual perception that the pudding would be “filling”.
These important characteristics contribute to the success
of bariatric surgery to limit caloric intake, and support
dietary recommendations for this population to limit
beverage intake to low or no calorie liquids [40].
Insulinogenic index, a dynamic measure of glucose
homeostasis was significantly lower at 2 weeks post-
surgery. Insulinogenic index has been shown to reflect
meal size in normal weight subjects, doubling with a two
fold increase in Kcal ingested [41]. We did not observe a
difference in insulinogenic index in the non-surgical
diabetic subjects consuming the two different pudding
volumes, suggesting that the insulin secretory response
was not properly responsive to glucose load in those
subjects. Our observations suggest that following sur-
gery the dynamic response to glucose ingestion was
improved.
Greater post- than pre-surgery insulin and C-peptide
excursions are generally observed when consuming large
volume liquid mixed meals, resulting in an increase in
post-surgery insulinogenic index (for example see [8,
10]). This observation has been interpreted to reflect an
improved response to glucose ingestion, although such a
response is unlikely to occur given the reduction in food
intake per meal following surgery. Despite a 50% reduc-
tion in caloric stimulus post-surgery, we observed simi-
lar insulin/C-peptide release over the first 30 min pre-
and post-surgery, suggesting that there was an increase
in insulin and C-peptide release per caloric unit con-
sumed, likely promoted by the significant increase in se-
cretion of GLP-1.
Insulin AUC, but not that for C-peptide, was lower
during the meal test post-surgery, indicating greater in-
sulin clearance by the liver. Reductions in fasting and
dynamic hyperinsulinema contribute to improved insulin
sensitivity in muscle and adipose tissue, which has been
documented to occur in parallel with weight loss [42].
Lower fasting glucose and smaller glucose response to
caloric challenge contribute to improved insulin sensitiv-
ity via reduced glucotoxicity in insulin target tissues.
Importantly, the improvements in glucose homeosta-
sis observed here were not achieved by simply redu-
cing the quantity and volume of test meal ingested,
as shown in the diabetic subjects that did not
undergo surgery.
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GLP-1 and PYY release during the meal test were
greatly increased following surgery, as has been observed
in a number of studies (reviewed in [43]). The enhanced
secretion of GLP-1 and PYY resulting from the rapid
transit of calories to the lower small intestine likely con-
tributed to the reduction in food intake via their satiat-
ing effects on gut function and the central nervous
system. The incretin effect of GLP-1 would be expected
to result in greater insulin secretion during the meal test.
Our observation that C-peptide release in response to
the post-surgery meal test was unchanged, despite inges-
tion of half of the caloric load, suggests that GLP-1 did
have an effect to promote greater insulin release, which
was subsequently and efficiently cleared from the circu-
lation by the liver.
A recent study in a small number of post-RYGB sur-
gery subjects noted that a liquid meal induced greater
increases in insulin and gut peptides than did a solid
meal of similar caloric content [44]. This likely reflected
the much faster absorption of calories provided by the li-
quid meal. We did not compare responses between solid
and liquid meals as our intent, in contrast to that of Lee
et al. [44], was not to determine a superior test method.
Conclusions
In summary we observed significant improvements in
both fasting and dynamic metabolic measures following
RYGB surgery in subjects with short duration diabetes.
The use of a solid mixed meal test in this study permit-
ted demonstration of improved glycemic responses to a
meal challenge under the naturalistic conditions of re-
duced caloric intake experienced by bariatric surgery
subjects. The metabolic improvements achieved with
RYGB cannot be achieved by simply reducing food in-
take as demonstrated in non-surgical subjects.
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